Kymera Therapeutics Outlines Key 2024 Objectives and

IRAK4 oral degrader KT-474 (SAR444656) expected to complete enrollment in both Phase 2 HS and AD studies in fourth quarter of 2024, with topline data...

Related Keywords

Boston ,Massachusetts ,United States ,Watertown ,American ,Nello Mainolfi ,Justine Koenigsberg ,Todd Cooper ,Kymera Therapeutics Inc ,Exchange Commission ,American Society Of Hematology ,Nasdaq ,Corporate Affairs ,Annual Healthcare Conference ,Janus Kinase ,American Society ,Healthcare Conference ,Private Securities Litigation Reform Act ,Kymera Therapeutics ,Kymera Therapeutic ,Annual Report ,Quarterly Report ,Vice President ,Nasdaq Kymr ,Nc ,